Inhibition of breast cancer metastasis to the lungs with UBS109

Area of Science:

• Pharmacology and Toxicology
• Oncology
• Cancer Metastasis Research

Background:

• Synthetic monocarbonyl analogs of curcumin (MACs) exhibit cytotoxicity against various cancers.
• Previous studies showed UBS109 (a MAC) prevents bone loss induced by breast cancer.
• Lung metastasis is a significant challenge in breast cancer treatment.

Purpose of the Study:

• To investigate the efficacy of UBS109 in inhibiting and preventing lung metastasis of breast cancer.
• To evaluate the anti-cancer activity of UBS109 in a preclinical lung metastasis model.

Main Methods:

• A breast cancer lung metastasis model was established using MDA-MB-231 cells injected into athymic nude mice.
• Mice were treated with UBS109 (5 or 15 mg/kg) or vehicle via intraperitoneal injection for 5 weeks.
• Cytotoxicity assays were performed in vitro, and pharmacokinetic analysis (Cmax) was conducted in vivo.

Main Results:

• UBS109 at 15 mg/kg significantly reduced lung metastasis, indicated by decreased lung weight and tumor nodules.
• UBS109 demonstrated complete eradication (100%) of MDA-MB-231 cells at 1.25 μM in vitro.
• Pharmacokinetic studies showed a Cmax of 432 ± 387 ng/mL at 15 min post-injection for UBS109 (15 mg/kg i.p.).

Conclusions:

• UBS109 effectively inhibits and prevents breast cancer lung metastasis in a preclinical mouse model.
• The in vitro and in vivo findings support UBS109's anti-metastatic and cytotoxic potential against breast cancer.
• UBS109 represents a promising therapeutic agent for managing breast cancer metastasis.